These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 26887594)

  • 21. Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells.
    Lu C; Yang D; Sabbatini ME; Colby AH; Grinstaff MW; Oberlies NH; Pearce C; Liu K
    BMC Cancer; 2018 Feb; 18(1):149. PubMed ID: 29409480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multifunctionalized iron oxide nanoparticles for selective targeting of pancreatic cancer cells.
    Trabulo S; Aires A; Aicher A; Heeschen C; Cortajarena AL
    Biochim Biophys Acta Gen Subj; 2017 Jun; 1861(6):1597-1605. PubMed ID: 28161480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
    Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
    Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sulforaphane counteracts aggressiveness of pancreatic cancer driven by dysregulated Cx43-mediated gap junctional intercellular communication.
    Forster T; Rausch V; Zhang Y; Isayev O; Heilmann K; Schoensiegel F; Liu L; Nessling M; Richter K; Labsch S; Nwaeburu CC; Mattern J; Gladkich J; Giese N; Werner J; Schemmer P; Gross W; Gebhard MM; Gerhauser C; Schaefer M; Herr I
    Oncotarget; 2014 Mar; 5(6):1621-34. PubMed ID: 24742583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer.
    Hage C; Rausch V; Giese N; Giese T; Schönsiegel F; Labsch S; Nwaeburu C; Mattern J; Gladkich J; Herr I
    Cell Death Dis; 2013 May; 4(5):e627. PubMed ID: 23661005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells.
    Zhao H; Duan Q; Zhang Z; Li H; Wu H; Shen Q; Wang C; Yin T
    J Cell Mol Med; 2017 Sep; 21(9):2055-2067. PubMed ID: 28244691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.
    Xu P; Yao J; He J; Zhao L; Wang X; Li Z; Qian J
    Oncotarget; 2016 Mar; 7(12):14831-40. PubMed ID: 26894380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells.
    Vaz AP; Ponnusamy MP; Rachagani S; Dey P; Ganti AK; Batra SK
    Br J Cancer; 2014 Jul; 111(3):486-96. PubMed ID: 25003666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma.
    Molejon MI; Tellechea JI; Loncle C; Gayet O; Gilabert M; Duconseil P; Lopez-Millan MB; Moutardier V; Gasmi M; Garcia S; Turrini O; Ouaissi M; Poizat F; Dusetti N; Iovanna J
    Oncotarget; 2015 Apr; 6(10):7408-23. PubMed ID: 25797268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
    Ju HQ; Li H; Tian T; Lu YX; Bai L; Chen LZ; Sheng H; Mo HY; Zeng JB; Deng W; Chiao PJ; Xu RH
    J Pineal Res; 2016 Jan; 60(1):27-38. PubMed ID: 26445000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.
    Yoshida K; Toden S; Ravindranathan P; Han H; Goel A
    Carcinogenesis; 2017 Oct; 38(10):1036-1046. PubMed ID: 29048549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
    Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
    Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells.
    Cioffi M; Trabulo SM; Sanchez-Ripoll Y; Miranda-Lorenzo I; Lonardo E; Dorado J; Reis Vieira C; Ramirez JC; Hidalgo M; Aicher A; Hahn S; Sainz B; Heeschen C
    Gut; 2015 Dec; 64(12):1936-48. PubMed ID: 25887381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice.
    Jiang SH; Li J; Dong FY; Yang JY; Liu DJ; Yang XM; Wang YH; Yang MW; Fu XL; Zhang XX; Li Q; Pang XF; Huo YM; Li J; Zhang JF; Lee HY; Lee SJ; Qin WX; Gu JR; Sun YW; Zhang ZG
    Gastroenterology; 2017 Jul; 153(1):277-291.e19. PubMed ID: 28315323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
    Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulin-like growth factor binding protein 3 chemosensitizes pancreatic ductal adenocarcinoma through its death receptor.
    Mofid MR; Gheysarzadeh A; Bakhtiyari S
    Pancreatology; 2020 Oct; 20(7):1442-1450. PubMed ID: 32830034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
    Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
    J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.